|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/28 | (2006.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 3463457 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17730627.1 |
| Date of filing the European patent application | 2017-06-01 | |
| (97) | Date of publication of the European application | 2019-04-10 |
| (45) | Date of publication and mention of the grant of the patent | 2023-06-28 |
| (46) | Date of publication of the claims translation | 2023-09-11 |
| (86) | Number | PCT/US2017/035492 |
| Date | 2017-06-01 |
| (87) | Number | WO 2017/210453 |
| Date | 2017-12-07 |
| (30) | Number | Date | Country code |
| 201662344880 P | 2016-06-02 | US |
| (72) |
FARSACI, Benedetto , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | PD-1 blokada su nivolumabu gydant atsparią Hodžkino limfomą |
| PD-1 BLOCKADE WITH NIVOLUMAB IN REFRACTORY HODGKIN'S LYMPHOMA |
| Payment date | Validity (years) | Amount | |
| 2025-05-05 | 9 | 208.00 EUR |
| 2026-06-01 |